PFEPfizerRunning, no new patients
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Advanced Malignancies · NSCLC · Ovarian Cancer · Urothelial Cancer · Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 77 (final count)
- Started
- Sep 29, 2021
- Main results expected
- Dec 31, 2026
- Fully finished
- Dec 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events leading to permanent discontinuation of study intervention
Measured over: Baseline up to approximately 5 years
Number serious adverse events reported for all participants
Measured over: Baseline up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05059522 · record last updated 2026-10-20 · checked 2026-11-09 15:36 UTC